Cilostazol Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg, 100 mg
Reference Brands: Pletal (USA/EU)
Category:
Heart Disorder
Cilostazol is available in Tablets
and strengths such as 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Cilostazol is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Cilostazol can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Cilostazol, sold under the brand name Pletal, is an oral phosphodiesterase III inhibitor used primarily to treat intermittent claudication in patients with peripheral arterial disease. It works by inhibiting platelet aggregation and dilating blood vessels, which helps improve blood flow to the limbs and reduces symptoms such as leg pain and discomfort during walking. If patients do not experience improvement after three months of therapy, discontinuation of the medication is generally recommended.
In addition to its primary indication, cilostazol is also used off-label for secondary stroke prevention due to its antiplatelet properties, though it has not received regulatory approval specifically for this purpose. Cilostazol is approved for use in the United States, the United Kingdom, and other regions for the management of intermittent claudication. Its dual action on platelets and vascular smooth muscle makes it a valuable option in cardiovascular care, particularly for improving exercise tolerance and quality of life in patients with peripheral vascular disease.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing